Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma
- 1 January 1993
- journal article
- review article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 11 (5) , 348-355
- https://doi.org/10.1002/stem.5530110502
Abstract
Recombinant human erythropoietin (rHuEPO) improves chronic anemia of cancer, but the proportion of patients who respond favorably to the treatment varies depending on the type of neoplasia. Preliminary data of the two malignancies with the highest response rates, namely, multiple myeloma and squamous cell carcinoma, are reported. Twenty patients with multiple myeloma and 14 with squamous cell carcinoma, who had presented with hemoglobin levels <11 g/dl, were treated with rHuEPO, 150 U/kg, three times/week. Response, defined as an increase of at least 2 g/dl hemoglobin within 12 weeks, was achieved by 15 myeloma patients (75%) and 11 patients with squamous cell carcinoma (79%). Tolerance of the treatment was excellent. The WHO performance status and quality of life improved in responders. The remarkably low levels of endogenous EPO in our patients with squamous cell carcinoma, most of whom had been treated with cisplatin‐or carbo‐platin‐containing regimens, suggest that anemia in these cases had been at least partly chemotherapy induced. In myeloma patients, the blunted EPO response to the anemic condition may have been partly caused by subclinical tubular insufficiency induced by toxic paraproteins. Future studies should aim to elucidate factors which are responsible for the inability of some patients to respond to rHuEPO treatment, even though in multiple myeloma and squamous cell carcinoma these non‐responders are a small minority.Keywords
This publication has 13 references indexed in Scilit:
- Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumorsAnnals of Oncology, 1993
- The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietinBritish Journal of Haematology, 1991
- Effects of various recombinant human hemopoietic growth factors (rhEpo, rhG-CSF, rhGM-CSF, rhIl-3) on the growth of peripheral blood progenitor cells (BFU-E, CFU-GM)Annals of Hematology, 1990
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990
- Decreased Erythropoietin Response in Patients with the Anemia of CancerNew England Journal of Medicine, 1990
- Erythropoietin beim multiplen MyelomDeutsche Medizinische Wochenschrift (1946), 1989
- The mechanism of action of erythropoietinThe International Journal of Cell Cloning, 1986
- Effect of cis‐diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cellsThe International Journal of Cell Cloning, 1985
- Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivativesEuropean Journal of Cancer and Clinical Oncology, 1984
- Role of the Kidney in ErythropoiesisNature, 1957